RBM15, METTL3, METTL14, ALKBH5, FTO, YTHDC1, and YTHDF2 are significantly differentially expressed between IDH-mutant and IDH-wildtype LGG. METTL3, FTO, and YTHDC1 are significantly differentially expressed between IDH-mutant and IDH-wildtype GBM. The risk signature comprises RBM15, WTAP, ALBKH5, FTO, YTHDC1, YTHDF1, and YTHDF2, all of which are independent prognostic markers and predictive of clinicopathological features and treatment sensitivity. Here, WTAP is linked to glioblastoma.